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Abstract. Optoacoustic (OA) imaging was employed to distinguish normal from neoplastic tissues in a trans-
genic murine model of prostate cancer. OA images of five tumor-bearing mice and five age-matched controls
across a 14 mm × 14 mm region of interest (ROI) on the lower abdomen were acquired using a reverse-mode
OA imaging system (Seno Medical Instruments Inc., San Antonio, Texas). Neoplastic prostate tissue was iden-
tified based on the OA signal amplitude in combination with spectral analysis of the OA radio frequency (RF)
data. Integration of the signal amplitude images was performed to construct two-dimensional images of the ROI.
The prostate tumors generated higher amplitude signals than those of the surrounding tissues, with contrast
ratios ranging from 31 to 36 dB. The RF spectrum analysis showed significant differences between the
tumor and the control mice. The midband fit was higher by 5 dB (62%), the intercept higher by 4 dB (57%)
and the spectral slope higher by 0.4 dB∕MHz (50%) for neoplastic prostate tissue compared to normal tissues
in the control mice. The results demonstrate that OA offers high contrast imaging of prostate cancer in vivo. © The
Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part
requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.JBO.19.5.056008]
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1 Introduction
Conventional imaging techniques for prostate cancer, such as
ultrasound, computed tomography, and magnetic resonance im-
aging, are used to identify abnormal areas in the prostate that are
then biopsied for a definitive diagnosis. These imaging tech-
niques do not reliably distinguish neoplastic from healthy pros-
tate tissue,1 leading to the large sampling error associated with
biopsies. A sensitivity of only 50% is estimated for these tech-
niques.2 The ability to accurately visualize neoplastic regions in
the prostate would improve biopsy targeting.
One of the most common techniques used for local grading
of the prostate is transrectal ultrasound (TRUS) because it can be
performed in real time. TRUS systems that utilize transducers in
the 5 to 7 MHz range3 can provide an acceptable resolution of
0.3 to 0.5 mm.4 However, the accuracy of this technique is
reported to be less than 50% to 60% with respect to the detection
of prostate cancer, due largely to the weak contrast at depth in
soft tissues.5–7 Conventional diagnosis is currently based solely
on the detection of gross anatomic properties of tissues. Recent
techniques have been developed that probe tissue microstructure
based on the spectral analysis of radio frequency (RF) data;8,9
however, these ultrasonic techniques do not provide any infor-
mation on the oxygen saturation or hemoglobin concentration of
the tissue, both of which are often altered with neoplasia.10,11
Pure optical imaging techniques, such as diffuse optical tomog-
raphy (DOT), are being investigated as possible targeting tech-
nologies for prostate cancer because of their ability to achieve
adequate contrast in soft tissues12,13 and their ability to measure
the oxygen saturation and hemoglobin concentrations of the tis-
sues. These techniques, however, suffer from strong light scat-
tering in biological tissues,12 resulting in either very limited
imaging depth (<1 mm), as in optical coherence tomography,
or limited resolution, as in DOT.10
Optoacoustic (OA) imaging overcomes the limitations
described by merging the contrast capability of optical imaging
with the resolution of ultrasound imaging.13 The quality of con-
trast in OA imaging is related to the optical properties, as in pure
optical imaging, and the thermomechanical properties of the tar-
get while the resolution and the maximum imaging depth are
scalable with the ultrasonic frequency, as in ultrasound imag-
ing.10 Consequently, OA imaging can provide high contrast
images with good resolution and penetration depth in soft
tissue.14,15
This emerging technique of OA exposes tissues to nanosec-
ond pulsed laser light, which induces tissue-generated acoustic
waves that are detected using wide band transducers.14,15 The
amplitude of an OA signal is largely dependent upon the optical
absorption properties of the target tissues. Solid tumours often
have increased blood flow, and therefore hemoglobin concentra-
tion, compared to healthy tissue.16,17 The OA approach takes
advantage of the high optical absorption of hemoglobin com-
pared with other tissue components at wavelengths in the visible
and near-infrared range to generate higher amplitude signals in
regions with higher hemoglobin concentrations.14,15 High reso-
lution images of the mouse vasculature have been published by a
number of groups.18–22 The frequency content of the generated
OA sound waves is broadband, and the detected signals are
limited by the finite bandwidth of the ultrasound imaging
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transducers and the frequency dependent attenuation of ultra-
sound in tissues.23 The frequency content of the OA RF signals
may reflect the anatomical properties of the absorbing structures
in a manner similar to the established techniques involving spec-
tral analysis of ultrasound RF data.9,24,25 Theoretical work has
shown that frequency characteristics of OA signals can differ-
entiate between normal and neoplastic tissues even when it is
not possible to resolve individual blood vessels;25 an important
consideration, since many OA imaging systems cannot resolve
individual blood vessels at the depth of the prostate in humans
[up to 10 cm (Ref. 26)].27,28
Spectrum analysis of ultrasound RF data and its relation to
tissue microstructure has been well described.29 The size of the
scattering structures compared to the wavelength of the incident
ultrasound modifies the frequency content of the backscattered
signal.30 Therefore, the frequency analysis of the ultrasound
backscatter RF signals holds useful information about the
medium subresolution structures. Large databases have been
developed, which are used with statistical classifiers to identify
specific tissue types from spectral image data.8 Analysis of the
frequency components of the RF signals improves the diagnos-
tic capabilities of conventional ultrasound imaging.8,29,31
RF data are collected in OA imaging wherein the size of the
absorbing structure contributes to the frequency content of the
OA signal.32 Spectrum analysis of RF OA signals generated by
blood vessel phantoms (cylindrical tubes filled with ink and
embedded into gelatin) shows a relationship between the spec-
tral components and the diameter of the cylinders.33 Spectrum
analysis of high-frequency OA signals from ex vivo ocular tissue
has also shown changes in the midband fit and slope around the
pigmented iris.34 Thus, the relationship between the spectral
components of OA data is likely linked to the physical proper-
ties of the target and, more specifically, the spatial distribution of
the hemoglobin concentration within the tissues. Hence, quan-
titative measurements may allow for databases to be established
for OAs, which, along with statistical classifiers, may be used to
identify tissue types from amplitude images and RF analysis.25 It
may also offer additional information on the target physiology
and vascular morphology.
In this work, we utilized a low resolution, high contrast
reverse-mode OA imaging system. OA amplitude and frequency
data were obtained from transgenic mice that develop prostate
adenocarcinoma and age-matched controls. We posit that the
analysis of the OA frequency components arising from nonre-
solvable tissue structures can be used to distinguish normal from
neoplastic tissues.
2 Materials and Methods
2.1 Animal Model
The transgenic adenocarcinoma of the mouse prostate
(TRAMP) model develops tumors similar to those reported in
the human clinical prostate disease.35,36 TRAMP mice develop
spontaneous autochthonous prostate cancer with distant site
metastasis.36 The tumor development begins as androgen-de-
pendent growth and then progresses to androgen-independent
growth, a progression similar to that of the human disease.37
The tumors originate and develop within the prostate gland,
which means they cannot be palpated or visualized in the animal
prior to imaging (unless evaluated in their late stages), unlike
many other implanted tumor models. At the tissue level, the
TRAMP model also displays prostatic intraepithelial neoplasia
prior to tumor formation.35
TRAMP mice form prostate tumors as early as 12 weeks of
age, with metastasis as early as 24 weeks of age.38 In this study,
we used five TRAMP mice and five age-matched controls
[C57BL/6J (wild type)] (Jackson Laboratories Inc., Bar
Harbor, Maine).
2.2 OA Image Acquisition
All procedures performed in this study were approved by the
Animal Care Committee of the University of Prince Edward
Island in accordance with the guidelines of the Canadian
Council for Animal Care. Imaging took place between 24
and 28 weeks of age. Prior to imaging, each animal was placed
in an anesthetic induction chamber and anesthetized with 2.5%
isoflurane in 100% oxygen. Once anesthetized, the hair on the
lower abdomen of the animal was removed using a chemical hair
remover (Nair®, Church & Dwight Corporation Inc., Ontario,
Canada) and the area to be imaged was marked using a perma-
nent marker. The animal was maintained under general anes-
thesia (2.5% isoflurane in 100% oxygen), secured to a
vertical holder, and lowered up to the neck in a water bath that
contained the laser fibers and transducer. Imaging in water is
required to optimize acoustic coupling.
The imaging system (Seno Medical Instruments Inc., San
Antonio, Texas) consists of a Nd:YAG pumped Ti:Sapphire
laser operating at 775 nm and an eight-element piezo-electric
annular transducer array (Fig. 1). The array offers dynamic
focusing capabilities, which allows for structures lying on the
array axis to be localized along a large depth of field.39
The transducer array has a central frequency of 5 MHz with a
−6 dB bandwidth of 60%, a focal point at 25 mm, a focal length
of 10 mm, and a focal width of 0.5 mm. The bifurcated optical
fiber bundle delivered 6 ns pulses at a 10 Hz repetition rate and
20 mJ of energy per pulse. This is below the maximum permis-
sible exposure limit of 100 mJ∕cm2 at 775 nm as per the
American National Standards Institute.40 Throughout the imag-
ing process, the mouse was held stationary as the fiber bundles
and transducer array performed a raster scan across the selected
area, moving in 0.2 mm steps and acquiring 4 OA signals at each
position for averaging. The OA data were acquired from a 14 ×
14 mm region of interest (ROI_scan) at the lower abdomen of
Fig. 1 The small animal OA imaging system. Laser optical path inter-
cepts at 25 mm from the transducer that is located beneath a camera
used for image positioning. The animal (target) remained stationary as
optoacoustic (OA) signals were acquired by a raster scan of a
14 mm × 14 mm region of the lower abdomen.
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the mice that included the prostate region. The ROI_scan was
defined by a marked outline drawn on the mouse. The total im-
aging time was approximately 1.4 h. This imaging time is a
result of the raster approach, which, for our system, requires
1 s acquisition time at each step (including averaging), and
there are approximately 4900 steps for each image.
Immediately following the image acquisition, each mouse
was euthanized with an intracardiac injection of sodium pento-
barbital (65 mg∕kg). Three TRAMP and age-matched control
mice pairs were flash frozen in liquid nitrogen, in an upright
position on the holder at all times to reduce organ migration.
The lower abdomen was dissected and 100 μm lateral cryosec-
tions were acquired for gross anatomical comparison with the
OA images using a cryostat. The other two TRAMP and
age-matched control pairs were immediately dissected follow-
ing euthanasia. The prostate, seminal vesicles, and any sus-
pected abnormal tissues were fixed in a standard biological
nitrogen fixation solution for histological processing. The tissue
was sectioned and examined for evidence of prostate adenocar-
cinoma. The ROI_scan that was marked using a permanent
marker prior to imaging was used to align the OA images
with the cryosection photographs and histological sections.
2.3 Signal Amplitude Analysis
For the signal amplitude analysis, OA data from a 3 μs time
window were extracted from each RF line. This time window
corresponded to a 5-mm depth, beginning 1 mm beneath the
front surface of the animal (and at the same depth in the age-
matched control). This removed the typically strong signals
acquired from the animal skin surface and included data
from tissue regions that included the prostate. The Hilbert trans-
form was applied to all RF data.27,41 The signal strength is pre-
sented as arbitrary units, and all data were collected with the
same constant gain settings.
In order to account for optical attenuation by tissues that
reduces the light available at depth for OA wave generation,
we have employed a depth-dependent signal correction to
each A-line. This is somewhat analogous to the use of time
gain controls in ultrasound imaging to account for acoustic
attenuation. However, optical attenuation is significantly greater
than the acoustic attenuation below 10 MHz in tissues.27
The large aperture fiber bundles produce uncollimated light
beams incident on the tissue surface. Hence, the subsurface flu-
ence IðzÞ at depth z is diffuse and, as such, can be described
using the effective attenuation coefficient, μeff , according to
Cox et al.42
IðzÞ ¼ Ioe−μeffz: (1)
An effective attenuation coefficient of 3.1 cm−1 was used as
reported for rat prostate tumors.43 The final form of the correc-
tion factor was
OAcorrðzÞ ¼ OAHTðzÞeμeffz: (2)
AMATLAB® (TheMathWorks Inc., Natick, Massachusetts)
based script was developed and used to apply the attenuation
estimate to the signals. Such a correction is important given
the variation in tumor depths that can occur among the
TRAMP mice cohort.
The signal within each 3 μs time window was integrated and
projected onto a two-dimensional (2-D) plane to form an image.
A 2 mm × 2 mmROIwas used for analysis (ROI_analysis). This
region size was chosen so that the ROI_analysis, if placed in the
center of the smallest tumor, would be on-tumor tissue despite an
estimated alignment uncertainty of 2mmbetween theOA images
and the cryosections/histological images. This alignment uncer-
tainty includes a 0.5 mm measured uncertainty in the camera
positioning, and a 1.5 mm estimated uncertainty due to potential
organ migration during image acquisition and prior to freezing.
Contrast values were determined between the on-tumor and
adjacent (off-tumor) tissues within the OA image of the TRAMP
mice, as well as between the tumor and the normal prostate
region of the age-matched control. Contrast was measured by
subtracting the average signal value within the ROI_analysis
on control tissue from the average signal value within the
ROI_analysis on tumor tissue and dividing by the standard
deviation.44,45
The tumor boundary was determined using the full width half
maximum (FWHM) of the signal in the 2-D image. Hence,
regions with signals greater than half the maximum signal
were defined as “on-tumor.”22
2.4 RF Spectrum Analysis
A spectrum analysis technique commonly performed on ultra-
sonic backscatter RF data was used for this analysis.29 To obtain
the sensitivity of the transducer at different frequencies, a cali-
brated power spectrum was obtained by using a 200-nm thick
gold film. The film was deposited onto a thin microscope cover
slide with no annealing. The gold film was used because it has a
broad OA power spectrum as well as a flat response in the
known bandwidth of the transducer thus providing a good mea-
sure of the transducer response.46 OA measurements were
obtained across an area of approximately 1 cm2 at 775 nm illu-
mination. A total of 20 OA signals were recorded. This is
referred to as the calibrated power spectrum.
The fast Fourier transform was applied to the tissue RF data
to calculate the RF echo spectrum. The mean of the squared
spectral magnitudes is the averaged power spectrum (APS).
The APS was converted into the decibel (dB) scale. A calibrated
power spectrum is subtracted from the converted APS to remove
any system-specific artifacts caused by the transducer character-
istics at the focus and system electronics.
Values were calculated over a 5-mm depth beginning 1 mm
before at the front surface of the tumor. The same 2 mm2
ROI_analysis used for the contrast measurements was used.
Values were calculated at each position (i.e., every 0.2 mm)
within the 2 mm2 ROI_analysis and were averaged. The same
acquisition plane was used on the TRAMP mice and age-
matched controls.
A sliding Hamming window was employed that has been
shown to significantly reduce noise in the spectrum analysis of
ultrasound data.29 The Hamming window had a width of 1 mm
and moved in 0.5 mm steps along the axial direction. A 1 mm
window was chosen so that approximately three acoustic wave-
lengths (at the central frequency of the transducer)were contained
in each window. The power spectrum at each location was the
average of the measured spectrum in each Hamming window.
A linear regression was performed on the APS between 1 and
6 MHz and the midband fit, slope, and intercept extracted from
the fit. This region was chosen based on the approximate linear-
ity of the dataset and the high signal-to-noise ratio (SNR of
5.3 dB) within these frequencies. The statistical spread of
these parameters for ultrasound RF data has been previously
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established by others.29 A paired t-test was used to compare the
spectral parameters between normal and neoplastic tissue.
3 Results
3.1 OA Imaging
Representative TRAMP and age-matched control cryosection
and integrated OA signal amplitude images are shown in
Fig. 2. Approximate areas imaged on the animals are repre-
sented by black outlines. The cryosection images of both sets
of control and TRAMP mice were taken from the same
depth beneath the surface of the animal, 6.0 and 7.9 mm, respec-
tively, which corresponds to the maximum coronal tumor
dimension in the TRAMP mice (determined from the cryosec-
tions). Each TRAMP image was normalized to its maximum
signal value, and each control image was normalized to the
maximum signal value from the image of its age-matched
TRAMP. The OA image of the TRAMP mouse in Fig. 2(b)
shows an increase in signal amplitude in the region of the
tumor and relatively sharp decreases in the signal at the border
of the tumor. The signals obtained from the control mouse are
typically <0.5 a.u. and therefore beneath our defined threshold
of tumor tissue (defined in Sec. 2 using the FWHM and there-
fore above 0.5 a.u.). The tumor of the second TRAMP mouse
was less vascularized compared to that of the first TRAMP
mouse and has therefore been outlined in Fig. 2(e) for easier
visualization. Again the tumor is visible in the corresponding
OA image, Fig. 2(f), and the OA predicted vertical and horizon-
tal dimensions are 7.0 and 6.0 mm, which reasonably agree with
actual dimensions.
OA contrast for tumor compared to adjacent normal, healthy
tissue ranged from 31 to 36 dB across the five TRAMP mice
(Table 1). The OA contrast for the tumor compared to the region
of the prostate on the age-matched control animal also ranged
from 31 to 36 dB. The uncertainties of the contrast values are
one standard deviation of the values measured within the boun-
daries of the ROI_analysis in the OA image.
The OA predicted maximum lateral tumor dimension deter-
mined using the FWHM approach and the dimensions deter-
mined from the cryosections for the five TRAMP mice are
summarized in Table 1. True tumor dimensions were measured
during cryosectioning using a ruler. Tumor dimensions (mea-
sured on cryosections) ranged from 6.0 to 9.0 mm. The results
show that the OA predicted tumor dimensions agree with the
cryosection tumor dimensions to within 0.5 mm in all five
TRAMP mice.
3.2 Frequency Spectrum Analysis
A representative calibrated and noncalibrated power spectra for
one OA dataset are shown in Fig. 3. A linear fit was applied to
the normalized spectrum between 1 and 6 MHz.
The midband fit, intercept, and slope values for the five
TRAMP mice and age-matched controls are presented in
Fig. 4 and Table 2. The data in Fig. 4 represent an average
of 100 spectral parameter values acquired within a
2 × 2 × 2 mm ROI for all five mice. Error bars represent one
standard deviation. Tumor tissues generate higher values of
all three components compared with normal tissues (adjacent
and control).
Mean and standard deviation values from all TRAMP mice
on the tumor and on the adjacent tissue from all the control mice
are presented in Table 2. There is a six-fold increase in midband
fit and a two-fold increase in slope values on the tumor com-
pared with the control. Significant differences (p < 0.05)
were found between all spectral components. No significant dif-
ference was found between the control and the adjacent spectral
parameter values.
Cross-sectional profiles of the slope across the lateral dimen-
sion of a TRAMP tumor and age-matched control are shown in
Fig. 5. Slope values are independent of signal strength (provided
Fig. 2 Coronal cryosection images of TRAMP tumor-bearing mice (a
and e) with maximum tumor diameters of 9.0 and 7.0 mm, and age-
matched control mice (c and g). Approximate areas imaged on ani-
mals are represented by black outlines. Corresponding coronal inte-
grated signal amplitude images of tumor-bearing TRAMP mice (b and
f) with OA predicted tumor diameters of 8.8 and 7.0 mm, respectively
and age-matched control mice (d and h). Both sets of OA images
(TRAMP and age-matched control) were normalized to the maximum
signal value of the TRAMP image. The tumor in the second TRAMP
mouse (e) is much less vascularized than that of the first TRAMP
mouse (a) and has been outlined for easier visualization.
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the SNR is adequate) and would remove the need to correct for
optical attenuation. Therefore, analyzing slope values may be a
more robust method of identifying tumor boundaries. The image
shows that there is a gradual increase in slope values from the
boundaries of the tumor to the center and variations within
the tumor.
4 Discussion
The goal of this study was to demonstrate the potential of OA
imaging to distinguish neoplastic prostate tissue in a transgenic
tumor model from normal tissue in a control model. The ampli-
tude and RF frequency components of the OA signals showed
significant differences between cancerous and normal tissues.
The results may arise from the principle that the amplitude
of the OA signal is largely affected by the optical absorption
of the target (determined by, e.g., blood vessel size, oxygenation
status), while the frequency component may be more related to
the geometrical properties of absorbing structures (e.g., blood
vessel size, oxygenation status, and spatial distribution).32
Our imaging approach of integrating OA signals within a
3 μs time window and projecting these values onto a 2-D
plane yielded OA images with tumor contrast of 31 to
36 dB. The OA predicted dimensions agree with the true dimen-
sions to within 0.5 mm. Further data from an increased number
of animals may allow a more precise estimate of these variables
to facilitate calibration of the OA data analysis.
The axial position of the front surface of the tumor in the OA
image correlated to within 0.5 mm of the position measured dur-
ing cryosectioning. The 2-D raster scan method of acquiring OA
signals results in limited axial penetration depth due to the large
optical attenuation in tissue (especially in tumor tissues due to
elevated hemoglobin concentration).43 To account for this opti-
cal attenuation, a depth dependent signal correction factor was
applied to the OA signals prior to analysis.
Theoretical models relating the spectral intercept and slope
for conventional ultrasound RF data and the tissue scattering
structures have been well established.8,29 For conventional ultra-
sound imaging, the spectral components, slope, intercept, and
midband fit are related to the physical characteristics of the tar-
get scatterer (e.g., the size, shape, acoustic impedance, and spa-
tial distribution of the scatterering sources).8 The primary
absorbing target for OA application in this paper is hemoglobin,
which is localized in blood vessels.
The amplitude of the OA signal strongly affects the ampli-
tude of the frequency spectrum, thereby affecting the midband
fit and intercept values while the slope should be independent of
amplitude (provided the signal-to-noise is adequate).47 The OA
signal amplitude is depth dependent due to high optical attenu-
ation in tissues. For example, tumors with similar OA character-
istics but positioned at different depths may yield different
midband and intercept values. Hence, correcting for changes
in fluence for variable target (i.e., tumor) depths is important.
The depth dependent signal correction applied to the OA signals
in this study represents an initial approach toward accounting for
the optical attenuation. Significant differences between spectral
parameters were found with and without the correction factor
(data not shown).
Differences in spectral components of neoplastic tissue com-
pared with healthy tissue have been reported for ultrasound RF
data.48 Neoplastic tissues have a different microstructure than
that of healthy tissue; for example, neoplastic tissues are
often denser than normal tissue and consist of more tortuous
vasculature.49 This leads to significant differences in the spectral
components associated with neoplastic tissue compared to many
healthy tissues.50
Poorly differentiated prostate tumors are characterized by
smaller vessels with greater microvessel density.51 Additionally,
the aggressiveness of the tumor has been associated with the
vessel diameter and microvessel density,51,52 which has been
demonstrated to be indicative of the chances of cancer survival
for several malignancies.53
A similar spectrum analysis technique for OAs has been
reported by Kumon et al. who found a significant increase in
the midband fit between on and off tumor but no significant
differences for the intercept and slope.54 Kumon et al. found
midband fit values were 8.8 dB higher on the tumor compared
with adjacent normal tissue. Similarly, we found midband fit
values were 6 dB higher on the tumor compared with adjacent
tissue. The slope values presented by Kumon et al. were
0.5 dB∕MHz higher on the tumor (with no significant difference
between the tumor and normal) compared with the slope values
of this study, which were 0.4 dB∕MHz higher on tumor tissue
and significantly different from normal tissue. Our study dem-
onstrates significant differences in all three spectral parameters
between on and off tumor. Furthermore, control animals were
used in this study to ensure that the OA signals adjacent to
the tumor were consistent with normal tissues and not affected
by the presence of the tumor.
Table 1 OA image contrast for five TRAMP mice and age-matched
controls, and lateral TRAMP tumor dimensions.
Animal
#









1 33 2 34 2 8.8 9.0
2 31 2 35 2 7.0 7.0
3 33 2 36 2 6.0 6.5
4 36 2 34 2 5.6 6.0
5 31 2 31 2 8.0 8.0
Fig. 3 Representative power spectrums. (a) Uncalibrated RF tissue
spectrum and calibration spectrum of the 5 MHz transducer. (b) The
calibrated tissue power spectrum and linear fit applied between 1 and
6 MHz.
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The cross-sectional profile of the slope across a TRAMP
tumor (Fig. 5) shows a gradual increase in the slope across
the tumor boundary. Slope values are independent of signal
strength (provided the SNR is adequate) and would remove
the need to correct for optical attenuation. Therefore, analyzing
the slope values may be a more robust method of identifying
tumor boundaries.
OA imaging has shown promising initial results for detecting
the presence of cancerous tumors with high contrast and
good resolution compared with conventional ultrasound
imaging.10,14,15 Using frequency spectrum analysis in combina-
tion with the current amplitude presentation of OA images may
offer potentially important information about the tumor (e.g.,
vascular density, diameter, etc.). In a clinical setting, OA imag-
ing (amplitude presentation) may be used to detect the presence
of a tumor and its position in the tissue/organ. The frequency
analysis of the RF signals from this tumor could then be per-
formed to obtain further information on its physiological proper-
ties that may be indicative of its aggressiveness and treatability.
Typical qualitative OA images, using only signal amplitude
information, are also subject to a variety of user- and system-
dependent factors (e.g., brightness/contrast, thresholding,
laser fluence, etc.) that make it difficult to compare between
studies. Frequency analysis described herein removes many
of these factors by compensating for the system response and
correcting for loss in optical fluence with depth.
The effective acquisition time of this system, ∼1 Hz, is due
to the existing firmware. Future work will involve decreasing
this delay time to optimize imaging time while minimizing
any detection of the signal generated by previous pulses.
Additional studies including a larger number of animals are
required to validate the contrast between the tumor, the preneo-
plastic tissue, and the healthy prostate as presented in this paper
and to determine the optimal analysis techniques for image gen-
eration and boundary determination. A framework for under-
standing how spectral features are related to tissue
physiology will need to be established along with statistical
methods for classifying different tissues.29 OA imaging of
prostate tumors obtained at varying time points may also
Fig. 4 Spectral components on tumor and adjacent to tumor for each TRAMP mouse and age-matched
control mouse. Midband fit (a), intercept (b), and slope (c). Each value represents an average of spectral
parameters acquired within a 2 × 2 × 2 mm region of interest.
Table 2 Average standard deviations of spectral components on tumor and adjacent to tumor for all TRAMP and for all control mice (N ¼ 5).
Spectral parameter Control Adjacent Tumor
t -test (p value)
tumor/control tumor/adjacent
OA midband fit (dB) −5 1 −5 1 1 1 0.0114 0.0040
OA slope (dB/MHz) 0.4 0.1 0.4 0.1 0.8 0.1 0.0026 <0.001
OA intercept (dB) −7 2 −8 1 −3 1 0.0155 <0.001
Note: OA, optoacoustic.
Fig. 5 Representative slope (dB/MHz) values across the lateral direc-
tion through a tumor in the TRAMP model (red) and in the control ani-
mal (blue). Vertical lines represent the boundaries of the tumor
obtained from FWHM measurements on the OA amplitude images.
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demonstrate the capability of these analysis techniques to not
only detect the presence of the tumor but to also give an indi-
cation of the extent of the disease.
5 Conclusions
This study reports that there are significant differences between
the amplitude and frequency content of OA signals between a
tumor and healthy tissue. The increased signal amplitude is due
to the increased vascularization within the tumor. The
differences in the frequency components, however, are likely
due to the combination of increased vascularization and vascular
heterogeneity (more tortuous and smaller vessels size) of tumor
tissues compared to healthy tissues. Frequency analysis, unlike
amplitude analysis, of OA signals provides information about
nonresolvable vascular structures, an important consideration
since many OA imaging systems cannot resolve individual
blood vessels at the depth of the prostate.27,28 Knowledge of
these vascular characteristics may aid in cancer diagnosis and
treatment planning. This report has demonstrated the utility
of standard pulse-echo spectrum analysis techniques for OA
characterization of normal and neoplastic tissues. The results
of this work contribute to the growing evidence-based support
for optoacoustics as a cancer imaging tool.
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